Clinical trial · Observational
Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
Real World Outcomes of Nivolumab + Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
NCT07079644CI-TRIAL-00092480completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BRAF/MEK inhibitors | Drug | — | UNRESOLVED |
| Immunotherapy monotherapy | Biological | — | UNRESOLVED |
| Nivolumab + Ipilimumab | Biological | Ipilimumab/Nivolumab Regimen | ALIAS |
| Nivolumab + Relatlimab | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- 1L Nivolumab + Relatlimab cohort
- interventionNames
- Biological: Nivolumab + Relatlimab
- label
- 1L Nivolumab + Ipilimumab cohort
- interventionNames
- Biological: Nivolumab + Ipilimumab
- label
- 1L Immunotherapy monotherapy cohort
- interventionNames
- Biological: Immunotherapy monotherapy
- label
- 1L BRAF/MEKs inhibitors cohort
- interventionNames
- Drug: BRAF/MEK inhibitors
Primary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants in the advanced melanoma cohort * Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either at initial diagnosis or via local or distant recurrence, and at least two clinic encounters evident in the database * Participants receiving Nivolumab + Relatlimab between March 18, 2022 and September 30, 2024 or other therapies (Nivolumab + Ipilimumab, immunotherapy monotherapy, BRAF/MEK inhibitors) between March 18, 2022 and November 30, 2024 (or date of the most recent data cut off) * Participants ≥18 years old on index date * Participants with ≥1 month of medical data after the index date (inclusive), unless patient died within this period Exclusion Criteria: * Participants with diagnosis of other primary cancers prior to the index date * Participants receiving medication in a clinical trial at any time prior to, on or after index date
References
Publications (0)
Data not yet available
No reference posted for this study.